Skip to main content
Top
Published in: Annals of Surgical Oncology 4/2011

01-04-2011 | Endocrine Tumors

Survival Implications of Cervical Lymphadenectomy in Patients with Medullary Thyroid Cancer

Authors: Emad Kandil, MD, Marta M. Gilson, PhD, Haytham H. Alabbas, MD, Anthony P. Tufaro, MD, Alan Dackiw, MD, PhD, Ralph P. Tufano, MD

Published in: Annals of Surgical Oncology | Issue 4/2011

Login to get access

Abstract

Background

The relationship between extent of cervical lymphadenectomy along with the number of involved lymph nodes (LNs) removed and overall survival has not been well documented in patients with medullary thyroid carcinoma (MTC). This study investigates whether the overall number of LNs removed and the number of metastatic LNs are independent prognostic factors for overall survival.

Methods

Data from patients with MTC in the Surveillance, Epidemiology, and End Results (SEER) registry database were examined. After categorizing the study population based on the number of overall LNs examined and the number of metastatic LNs, survival estimates were compared. The total number of examined LNs and their histopathological status were analyzed for their prognostic value in estimating overall survival.

Results

593 patients were included in this study. Those with all negative LNs had the best overall survival; those with LNs examined and at least one positive LN had worst overall survival (p < 0.0001). The total number of examined LNs for both groups with negative and positive LNs was not associated with improved survival outcome (p = 0.41). In node-positive patients, each additional positive LN was significantly associated with an increase in overall mortality [hazard ratio (HR) = 1.05, 95% confidence interval (CI) = 1.02–1.08].

Conclusions

Cervical LN metastases conferred an independent risk for worse survival rate in MTC. Cervical lymphadenectomy is important for staging and regional disease control, however the extent of lymph node dissection, the overall number of lymph nodes removed along with removal of an increased number of involved lymph nodes do not confer a survival advantage. Future prospective studies are needed.
Literature
1.
go back to reference Harris PE. The management of thyroid cancer in adults: a review of new guidelines. Clin Med. 2002;2(2):144–6.PubMed Harris PE. The management of thyroid cancer in adults: a review of new guidelines. Clin Med. 2002;2(2):144–6.PubMed
2.
go back to reference Kendall-Taylor P, Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2003;58(4):400–2.CrossRef Kendall-Taylor P, Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2003;58(4):400–2.CrossRef
3.
go back to reference American Thyroid Association Guidelines Task Force, Kloos RT, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565–612.PubMedCrossRef American Thyroid Association Guidelines Task Force, Kloos RT, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565–612.PubMedCrossRef
5.
go back to reference Franc S, et al. Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin Endocrinol (Oxf). 2001;55(3):403–9.CrossRef Franc S, et al. Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin Endocrinol (Oxf). 2001;55(3):403–9.CrossRef
6.
go back to reference Chen H, et al. Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection. Ann Surg. 1998;227(6):887–95.PubMedCrossRef Chen H, et al. Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection. Ann Surg. 1998;227(6):887–95.PubMedCrossRef
7.
go back to reference Kebebew E, et al. Extent of disease and practice patterns for medullary thyroid cancer. J Am Coll Surg. 2005;200(6):890–6.PubMedCrossRef Kebebew E, et al. Extent of disease and practice patterns for medullary thyroid cancer. J Am Coll Surg. 2005;200(6):890–6.PubMedCrossRef
9.
go back to reference Ball DW. Medullary thyroid cancer, monitoring and therapy. Endocrinol Metab Clin North Am. 2007;36(3):823–37.PubMedCrossRef Ball DW. Medullary thyroid cancer, monitoring and therapy. Endocrinol Metab Clin North Am. 2007;36(3):823–37.PubMedCrossRef
10.
go back to reference Saad MF, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore). 1984;63(6):319–42. Saad MF, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore). 1984;63(6):319–42.
11.
go back to reference Gharib H, et al. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract. 2006;12(1):63–102.PubMed Gharib H, et al. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract. 2006;12(1):63–102.PubMed
12.
go back to reference Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107(9):2134–42.PubMedCrossRef Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107(9):2134–42.PubMedCrossRef
13.
go back to reference Kebebew E, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88(5):1139–48.PubMedCrossRef Kebebew E, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88(5):1139–48.PubMedCrossRef
14.
go back to reference Pelizzo MR, et al. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol. 2007;33(4):493–7.PubMedCrossRef Pelizzo MR, et al. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol. 2007;33(4):493–7.PubMedCrossRef
15.
go back to reference Fialkowski E, DeBenedetti M, Moley J. Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg. 2008;32(5):754–65.PubMedCrossRef Fialkowski E, DeBenedetti M, Moley J. Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg. 2008;32(5):754–65.PubMedCrossRef
16.
go back to reference Quayle FJ, Moley JF. Medullary thyroid carcinoma: management of lymph node metastases. Curr Treat Options Oncol. 2005;6(4):347–54.PubMedCrossRef Quayle FJ, Moley JF. Medullary thyroid carcinoma: management of lymph node metastases. Curr Treat Options Oncol. 2005;6(4):347–54.PubMedCrossRef
17.
go back to reference Moley JF, et al. Reoperation for recurrent or persistent medullary thyroid cancer. Surgery. 1993;114(6):1090–5 (discussion 1095–6).PubMed Moley JF, et al. Reoperation for recurrent or persistent medullary thyroid cancer. Surgery. 1993;114(6):1090–5 (discussion 1095–6).PubMed
Metadata
Title
Survival Implications of Cervical Lymphadenectomy in Patients with Medullary Thyroid Cancer
Authors
Emad Kandil, MD
Marta M. Gilson, PhD
Haytham H. Alabbas, MD
Anthony P. Tufaro, MD
Alan Dackiw, MD, PhD
Ralph P. Tufano, MD
Publication date
01-04-2011
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 4/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1363-y

Other articles of this Issue 4/2011

Annals of Surgical Oncology 4/2011 Go to the issue